GlassScriptPhysician profile
Khaled E Fernainy
NPI 1457554586
$1,189.84
in general payments reported to CMS, 2019-2025
11 companies · $64.11 in 2025
The $64.11 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $84.22 · 2023: $514 · 2024: $156 · 2025: $64.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $208.22 | 2023 | Hemosphere |
| Inari Medical, INC. | $188.00 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $162.89 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2019 | |
| Portola Pharmaceuticals, LLC | $124.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.54 | 2019 | |
| Vapotherm INC | $97.00 | 2023 | Vapotherm |
| Astrazeneca Pharmaceuticals LP | $84.22 | 2020 | |
| Abbott Laboratories | $46.49 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| La Jolla Pharmaceutical Company | $21.23 | 2023 | Giapreza |
| Daxor Corporation | $11.20 | 2025 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Fernainy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.